MIF and Uterine leiomyoma: In the current study, we employ MIF at varying concentrations to treat primary uterine leiomyoma cells isolated from patients diagnosed with uterine leiomyoma, in order to determine whether PRA could be a therapeutic option for the treatment of uterine leiomyoma.